In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...

Most previous CRISPR trials have focused on knocking ... given the setbacks seen in a study of another base editing treatment from Verve Therapeutics last year, which forced the company to restart ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports.

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing ...